Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastiano Buti

Showing results (221-230 of 336) with videos related to

Pageof 34
Sort By:
Immunotherapy|March 23, 2018
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 studyAlessio Cortellini, Melissa Bersanelli, Sebastiano Buti, et al.
Journal of Geriatric Oncology|August 13, 2025
Effectiveness of nivolumab-based immunotherapy and prognostic stratification by the Meet-URO score in real-world older patients with metastatic renal cell carcinomaVeronica Murianni, Marina Campione, Malvina Cremante, et al.
Clinical & Experimental Metastasis|June 8, 2024
Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 projectAlessandro Rizzo, Sebastiano Buti, Patrizia Giannatempo, et al.
Clinical Genitourinary Cancer|November 6, 2023
Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9)Alessandra Damassi, Malvina Cremante, Alessio Signori, et al.
Targeted Oncology|August 10, 2022
Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination TherapiesMatteo Santoni, Javier Molina-Cerrillo, Zin W Myint, et al.
Clinical Medicine Insights. Oncology|July 22, 2021
Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study)Melissa Bersanelli, Sebastiano Buti, Alessio Cortellini, et al.
European Urology|October 4, 2021
Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES StudyCristina Masini, Cinzia Iotti, Ugo De Giorgi, et al.
Targeted Oncology|August 29, 2020
Correction to: Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional AnalysisRoberto Iacovelli, Chiara Ciccarese, Gaetano Facchini, et al.
Expert Review of Anticancer Therapy|November 5, 2021
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21)Alessia Mennitto, Emma Zattarin, Massimo Di Maio, et al.
Clinical Genitourinary Cancer|January 10, 2022
Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone StudyDaniele Raggi, Patrizia Giannatempo, Laura Marandino, et al.
Pageof 34

Showing results (221-230 of 336) with videos related to

Sort By:
Pageof 34
Immunotherapy|March 23, 2018
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 studyAlessio Cortellini, Melissa Bersanelli, Sebastiano Buti, et al.
Journal of Geriatric Oncology|August 13, 2025
Effectiveness of nivolumab-based immunotherapy and prognostic stratification by the Meet-URO score in real-world older patients with metastatic renal cell carcinomaVeronica Murianni, Marina Campione, Malvina Cremante, et al.
Clinical & Experimental Metastasis|June 8, 2024
Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 projectAlessandro Rizzo, Sebastiano Buti, Patrizia Giannatempo, et al.
Clinical Genitourinary Cancer|November 6, 2023
Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9)Alessandra Damassi, Malvina Cremante, Alessio Signori, et al.
Targeted Oncology|August 10, 2022
Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination TherapiesMatteo Santoni, Javier Molina-Cerrillo, Zin W Myint, et al.
Clinical Medicine Insights. Oncology|July 22, 2021
Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study)Melissa Bersanelli, Sebastiano Buti, Alessio Cortellini, et al.
European Urology|October 4, 2021
Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES StudyCristina Masini, Cinzia Iotti, Ugo De Giorgi, et al.
Targeted Oncology|August 29, 2020
Correction to: Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional AnalysisRoberto Iacovelli, Chiara Ciccarese, Gaetano Facchini, et al.
Expert Review of Anticancer Therapy|November 5, 2021
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21)Alessia Mennitto, Emma Zattarin, Massimo Di Maio, et al.
Clinical Genitourinary Cancer|January 10, 2022
Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone StudyDaniele Raggi, Patrizia Giannatempo, Laura Marandino, et al.
Pageof 34